Should dolutegravir always be withheld in people with HIV on dolutegravir with incident diabetes mellitus? A case report

Mostrar otras versiones (1)

Dolutegravir (DTG), an integrase strand transfer inhibitor is currently the recommended first and second line anti-retroviral therapy (ART) anchor agent by the World Health Organization. This followed widespread reports of primary resistance to non-nucleoside reverse transcriptase inhibitors. Despit...

Descripción completa

Detalles Bibliográficos
Autores principales: Mulindwa, Frank, Castelnuovo, Barbara, Brusselaers, Nele, Bollinger, Robert, Yendewa, George, Amutuhaire, Willington, Mukashaka, Claudine, Schwarz, Jean-Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10479436/
https://www.ncbi.nlm.nih.gov/pubmed/37674704
http://dx.doi.org/10.21203/rs.3.rs-3218404/v1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10479436/
https://www.ncbi.nlm.nih.gov/pubmed/37674704
http://dx.doi.org/10.21203/rs.3.rs-3218404/v1

Ejemplares similares